Warning letter
Jilin Shulan Synthetic Pharmaceutical Co. Ltd. [ARCHIVED]: warning letter of May 13, 2010
FDA warning letter 102525 · Center for Drug Evaluation and Research
Key facts
| Reference number | 102525 |
|---|---|
| Company | Jilin Shulan Synthetic Pharmaceutical Co. Ltd. [ARCHIVED] |
| Subject | CGMP for Deviations/Adulterated |
| Issue date | May 13, 2010 |
| Posted date | May 13, 2010 |
| Issuing office | Center for Drug Evaluation and Research |
| Product type | Drugs |
| Inspection city | Jilin |
| Inspection start date | Aug 24, 2009 |
| Letter on fda.gov | web.archive.org |
At a glance
- OAI Linked inspection classification
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: